Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/85035
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Osama, Sara | - |
dc.contributor.author | Wirth, Francesca | - |
dc.contributor.author | Zahra, Graziella | - |
dc.contributor.author | Barbara, Christopher | - |
dc.contributor.author | Xuereb, Robert G. | - |
dc.contributor.author | Camilleri, Liberato | - |
dc.contributor.author | Azzopardi, Lilian M. | - |
dc.date.accessioned | 2021-12-03T08:44:21Z | - |
dc.date.available | 2021-12-03T08:44:21Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Osama, S., Wirth, F., Zahra, G., Barbara, C., Xuereb, R. G., Camilleri, L., & Azzopardi, L. M. (2021). CYP2C19* 2 genetic polymorphism and incidence of in-stent restenosis in patients on clopidogrel: A matched case-control study. Drug Metabolism and Personalized Therapy, DOI: 10.1515/dmpt-2021-0160. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar/handle/123456789/85035 | - |
dc.description.abstract | Objectives The cytochrome P450 2C19*2 (CYP2C19*2) genetic polymorphism is associated with reduced clopidogrel bioactivation, increasing the risk of atherothrombotic complications after percutaneous coronary intervention (PCI). In-stent restenosis (ISR) is a complication that limits the long-term prognosis of PCI. The aim was to investigate the association between presence of the CYP2C19*2 allele and ISR within one-year after PCI in patients prescribed dual antiplatelet therapy with aspirin and clopidogrel. | en_GB |
dc.description.abstract | Methods Sixty patients with angiographically-confirmed drug eluting stent (DES)-ISR within 12 months post-PCI when on DAPT with aspirin and clopidogrel were retrospectively identified (Cases). Another 60 patients with no documented ISR post-PCI in the study period (Controls) were case-matched for age, gender, ethnicity, diabetes mellitus and estimated glomerular filtration rate value, and were invited for CYP2C19*2 genotyping. The association between presence of the CYP2C19*2 allele and ISR was analysed using the Fisher’s Exact test and binary logistic regression. | en_GB |
dc.description.abstract | Results Twenty-six (43.3%) cases and 5 (8.3%) controls were carriers of one or two CYP2C19*2 alleles. As to non-carrier status of the CYP2C19*2 allele, 34 (56.7%) cases and 55 (91.7%) controls were identified. The association between CYP2C19*2 carrier status and DES-ISR within one-year post-PCI was statistically significant (p<0.001) in both the univariate and multivariate analysis. | en_GB |
dc.description.abstract | Conclusions The proportion of patients who were carriers of one or two CYP2C19*2 alleles who presented with DES-ISR within one-year post-PCI while on clopidogrel was significantly higher compared to patients with no documented ISR. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | The Gruyter | en_GB |
dc.rights | info:eu-repo/semantics/restrictedAccess | en_GB |
dc.subject | Clopidogrel | en_GB |
dc.subject | Coronary arteries -- Stenosis | en_GB |
dc.subject | Chromosome polymorphism | en_GB |
dc.subject | Pharmacogenetics | en_GB |
dc.subject | Genetic polymorphisms | en_GB |
dc.subject | Cardiovascular Agents | en_GB |
dc.title | CYP2C19* 2 genetic polymorphism and incidence of in-stent restenosis in patients on clopidogrel : a matched case-control study | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.identifier.doi | 10.1515/dmpt-2021-0160 | - |
dc.publication.title | Drug Metabolism and Personalized Therapy | en_GB |
Appears in Collections: | Scholarly Works - FacM&SPha Scholarly Works - FacSciSOR |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
10.1515_dmpt-2021-0160.pdf Restricted Access | 297.33 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.